Patrick Forde
@FordePatrick
Followers
5,501
Following
2,082
Media
273
Statuses
2,783
Lung cancer & Mesothelioma @HopkinsThoracic @HopkinsKimmel Immunotherapy believer. 🇮🇪 🇺🇸
Baltimore, MD
Joined June 2019
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Mother's Day
• 1314944 Tweets
CDMX
• 157204 Tweets
Mauro
• 144917 Tweets
Clara
• 121887 Tweets
#DebateChilango
• 107104 Tweets
Emma
• 71880 Tweets
Nuggets
• 69921 Tweets
Taboada
• 54385 Tweets
Murray
• 48311 Tweets
Wolves
• 47669 Tweets
つばさの党
• 44186 Tweets
Iztapalapa
• 42721 Tweets
Denver
• 34863 Tweets
Jokic
• 34779 Tweets
Cruz Azul
• 28570 Tweets
Minnesota
• 26326 Tweets
Rayados
• 25991 Tweets
Pumas
• 25422 Tweets
家宅捜索
• 23352 Tweets
Monterrey
• 23149 Tweets
Tigres
• 22425 Tweets
Oilers
• 16880 Tweets
Gobert
• 16699 Tweets
LOSE MY BREATH REMIXES OUT NOW
• 15123 Tweets
Jordi
• 13602 Tweets
バンドリ
• 13595 Tweets
Gambino
• 13198 Tweets
#Canucks
• 13185 Tweets
#ほっともっと16周年
• 11814 Tweets
Ernestina Godoy
• 11759 Tweets
#ElectionDay
• 10506 Tweets
Pinned Tweet
Patient-centered summary of the
#CheckMate816
neoadjuvant chemo-immunotherapy clinical trial. This is a new treatment for patients with stage 1-3 non-small-cell lung cancer that can be removed by surgery. The summary may be useful for clinicians & patients.
#lcsm
@LUNGevity
14
107
287
Today at
#AACR21
I was honored to present results of the phase 3 CheckMate 816 neoadjuvant chemo-nivo lung cancer trial on behalf of all the colleagues, patients & families who made it possible. In this thread I will discuss why we did the study, results and next steps/
30
149
527
Chemo-immunotherapy for earlier stage lung cancer approved! 8yrs have flown since our 1st trial of neoadj nivo began, thanks to many incl
@SU2C
@AACR
@bmsnews
@LUNGevity
Most of all pts with a leap of faith to take part in cancer trials, this is for you!
11
70
300
Today, CheckMate 816, a phase 3 trial of neoadjuvant chemo + nivolumab immunotherapy was published i - this was a global effort to improve the lives of pts dealing with newly diagnosed surgical lung cancer.
12
86
283
Delighted to see 7 yrs of work on chemo-immunotherapy for
#mesothelioma
come to fruition today in
@NatureMedicine
! Developed within
@eaonc
@PrECOGonc
PrE0505 was a investigator-initiated collaboration across 15 academic and community cancer centers. 1/
15
34
159
Lung cancer in the 2020s is the breast cancer of the 1990s and 2000s?
7
42
158
After a long and hard winter for so many the cherry blossoms have shown up
@HopkinsMedicine
!
3
14
131
Thanks
@JulieBrahmer
I am so grateful for the support of my colleagues near and far, family and friends over so many years, ar scáth a chéile a mhaireann na daoine!
Celebrating Dr Forde’s promotion to professor! I’m so proud of his amazing work and grateful for an amazing colleague and friend.
@HopkinsThoracic
dream team!
22
7
98
18
5
134
Remember our 2018
@NEJM
paper on neoadjuvant nivo for surgical lung cancer? In
@CCR_AACR
today we report on those pts 5 years on, no pts who had a tumor major path response (MPR) had active tumor. Thanks to
@Sam_Rosner_
@Joshua_Reuss
@ChaftJamie
& all pts who participated!
#lcsm
Neoadjuvant nivolumab showed long-term benefit for patients with NSCLC, according to a five-year follow-up published in
@CCR_AACR
.
@FordePatrick
@Sam_Rosner_
@hopkinskimmel
@HopkinsThoracic
0
19
44
4
31
123
Warm spring night
@HopkinsMedicine
and the Dome is glowing turquoise for
#lungforce
week recognizing our patients and families dealing with lung cancer - the most common cause of cancer death for women and men
@LungAssociation
@hopkinskimmel
3
14
119
Nivo ✅ Durva ✅- Durvalumab Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer
#lcsm
2
35
114
Tribute to all our patients and predecessors (typified by Dan Ihde) who took the leap of faith to pursue treatment and study of lung cancer when options were so limited
#LCSM
Congratulations to Dr.
@FordePatrick
- recipient of the 2022 Daniel C. Ihde Lectureship for Medical Oncology! Very well deserved!
#WCLC22
17
12
138
12
5
111
ALINA adjuvant alectinib vs chemo for ALK pos resected lung cancer. Again unfortunate re data leak but sneak peak looks good. HR 0.24 favoring alectinib 30% improvement in DFS at 3 yrs. Adjuvant chemo followed by alectinib likely the path forward.
9
35
109
9
59
110
Results of 1st platform neoadjuvant IO trial in lung cancer led by Dr. Tina Cascone! We believe this trial design & in depth science will deliver valuable & rapid info to prioritize new IO agents in early & late stage cancer. NeoCOAST2 already underway - !
Now in
@CD_AACR
: Neoadjuvant Durvalumab Alone or Combined w/Novel
#ImmunoOncology
Agents in Resectable
#LungCancer
: The Phase 2 NeoCOAST Platform Trial - by Tina Cascone,
@FordePatrick
, et al.
@MDAndersonNews
@bloombergkimmel
@HopkinsKimmel
#Immunotherapy
0
5
30
1
28
109
Good to see former German leader is keeping busy in her retirement, keeping to deadlines as well, 15 days to write the paper!
10
5
107
Pre 2024 Ireland Lung Cancer Conference exercise program with Drs.
@JulieBrahmer
&
@DrJNaidoo
!
#AILCC24
#lcsm
🇮🇪
2
4
100
Adjuvant Pembro improves DFS in resected NSCLC! Headline DFS curve looks good and similar to Imp010 in all comers, subsets a bit counterintuitive (maybe a lesson not to look too closely at subsets?). Notably more PD-L1 pos tumors in this trial than CM-816 or Imp010
#LCSM
8
35
100
Tour de force CheckMate 816 work led by immunopathologists
Is Drs. Julie Stein & Janis Taube. Benefit from neoadjuvant therapy for lung cancer is much more than just pathologic complete response, here is the most in depth analysis of path response reported to date.
#LCSM
A phase 3 CheckMate 816 trial analysis shows that the depth of pathologic response is correlated with event-free survival following neoadjuvant immunotherapy + chemotherapy, supporting pathological response as a biomarker of survival
1
27
54
2
37
99
Congratulations to Irish medical oncology specialist trainee graduates awarded
@ASCO
@ConquerCancerFd
Young Investigator Awards today at
#ASCO2023
Drs.
@EmilyHarrold6
@ferguskeane2
&
@JaneSYSui
!
3
25
99
Neoadjuvant nivolumab plus chemo improves event-free survival for surgical NSCLC! Allied to positive data on pathological complete response (improved from 2.2% to 24%) & more lung sparing surgery, great news for patients w stage 1-3 lung cancer!
#lcsm
1
27
94
Lesson in leadership on St. Patrick’s Day
WATCH: Taoiseach Leo Varadkar delivers Ministerial Broadcast to the country about the Covid-19 pandemic | Read more:
379
2K
6K
1
9
94
Clear presentation from Dr. Heymach of Aegean results. Similar pCR and EFS HRs so far to CM816 though it’s early days, unclear if there is going to be a benefit from adjuvant IO. EFS by pCR status still awaited. Congratulations to all the patients & investigators.
#LCSM
1
38
94
Outstanding from Drs.
@MARIANOPROVENCI
& colleagues
@gecp_org
@NEJM
today.
#NADIM2
trial in surgical lung cancer. 85% 2yr survival in stage III lung cancer, another milestone on the road to curing lung cancer of all stages!
#lcsm
5
34
92
CheckMate 77T - phase 3 trial of neoadj chemo-nivolumab followed by adjuvant nivolumab is pos for event-free survival. Results may help delineate contribution of adjuvant PD-1 blockade after neoadjuvant chemo-PD1 when looked at in context of CM816.
#lcsm
2
34
93
Two truly outstanding thoracic oncology clinician scientists are on the ballot for the
@AACR
board of directors this year, Dr.
@christine_lovly
& Dr. Alice Shaw, and luckily we can vote for both of them, get voting everyone!
#LCSM
0
15
92
My father was a carpenter who died from cancer, I was the first to complete a doctoral degree in my family. We lose so much by not supporting early career scientists
#LCSM
First-generation students, whose parents do not have degrees, are under-represented on MD-PhD programmes and need better support, argue
@BriChristophers
and colleagues at
@TriIMDPhD
#firstgen
1
73
199
0
9
92
After yesterday at
#ASCO23
we know that either ipi nivo or chemo-IO are likely better than chemo alone. Our trial
#dream3r
active across Aus/NZ & USA now addressing which of those regimens, chemo-IO or doublet IO are best. Pts and oncologists please consider!
#mesothelioma
7
28
90
Overall survival benefit from immunotherapy in surgical lung cancer!
@DoctorJSpicer
w results of
#KN671
- highlights multidisciplinary achievement for our pts. Caveats are do we need adjuvant & only 50% IO at relapse in control, but also time to step back & recognize a milestone!
1
25
90
Vaccine hesitancy is almost non-existent in Ireland, lowest rate of eligible adult uptake by county is 82%. Many of these counties are as rural as counties across the US with uptake <40%.
5
14
89
On the day we hear about another positive neoaduvant immunotherapy trial in lung cancer, our melanoma colleagues publish a trial suggesting the neoadjuvant (before surgery) part is crucial. A new dawn for interdisciplinary cancer care?
#LCSM
2
18
89
4
3
86
Lots of data coming soon in early stage lung cancer
@myESMO
including pivotal phase 3 trial results presented by Drs. Tina Cascone &
@bensolomon1
, neoadj nivo ipi & 3yr data from
#CM816
by
@DrMarkAwad
@MARIANOPROVENCI
& OS from
#KN671
by
@DoctorJSpicer
!
#ESMO23
: That exciting time of the year 🙌Almost all late-breaking abstract titles and authors are now online. Head to the programme and check out all the impressive science you can look forward to. This year we received 4,565 abstracts, an increase of +30% (YOY). See you in…
2
56
157
5
28
85
Tropion Lung01 - phase 3 trial of DatoDXD vs docetaxel in pretreated NSCLC. PFS 4.4m DatoDXD vs. 3.7m docetaxel. Stomatitis a concern with datodxd. Unfortunately not yet the major advance we had been hoping to see.
#lcsm
6
26
84
Neoadjuvant immunotherapy closer to a reality for surgical lung cancer! U.S. FDA Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
3
40
82
@hopkinskimmel
alumni on tour! Great to meet up Drs.
@ValsamoA
@RoisinMConnolly
&
@DrJNaidoo
all together again at
#ailcc22
in Dublin, Ireland!
3
6
81
The I-95 retreat at
#TTLC23
Georgetown &
@HopkinsThoracic
! Missing a few others but next year!
4
7
81
Out now in
@JTOonline
excellent work from Drs.
@ValterTorri
Hines, Cameron &
@marinagarassino
over 2500 pts in neoadjuvant & perioperative trials to date, pCR appears predictive of EFS, early days for OS.
#lcsm
0
31
79
Neoadjuvant chemo-nivolumab is now approved for stage IB-III lung cancer in USA, Canada, China, Australia, UK! Just out, an open access plain language manuscript on CM-816, providing the results in an accessible manner for patients & families!
#LCSM
1
29
79
Interesting, immunotherapy first is better than targeted therapy for BRAF V600 melanoma. I would not be surprised if the same were true in BRAF V600 lung cancer.
7
17
78
Neostar strikes again, led by Dr. Tina Cascone! Out now in
@NatureMedicine
neoadjuvant chemo-ipi-nivo in resectable lung cancer. The exciting study results here & commentary from
@michaelconroy
Exciting times!
#LCSM
0
32
79
Adding neoadjuvant nivo to chemo improved pCR, radiographic response & did not impair surgery. We await results for EFS & eventually OS however the data today are encouraging. My sincere gratitude to our pts, my colleagues, and mentors who brought this study to fruition.
#lcsm
5
16
78
Q. What happens if you don’t have surgery after neoadjuvant chemo-nivo for lung cancer? A. In
#CM816
you likely still have a better outcome with chemo nivo than chemo alone. See
@DoctorJSpicer
poster & discussion at
#ASCO23
- abstract just released!
5
18
78
#AACR22
New Orleans April 11 (3 weeks today!) = Key data in resectable/surgical lung cancer. Dr.
@nicogirardcurie
will present the results of CheckMate816 trial of neoadjuvant chemo-immunotherapy recently FDA approved and now in NCCN guidelines! 1/3
2
13
77
PEARLS (1 yr of pembro immunotherapy after surgery for lung cancer) study positive for DFS in full study population, PD-L1 breakdown will be interesting. This study reflects real world population more than IMpower010, allowing adj chemo/no adj chemo.
#lcsm
0
24
77
Invigorating post
#AILCC22
conference cliff walk, thanks so much to
@JackWestMD
@BernadineWest12
@peters_solange
@ValsamoA
@Alfdoc2
(in spirit!) for joining us in Dublin!
2
7
77
Excellent discussion of KN671 & CM816 from Dr.
@DrJNaidoo
@RCSI_Irl
🇮🇪! We are now improving OS in early stage lung cancer, how can we reach higher!
3
23
77
Chemo plus pembrolizumab improves survival for pts with newly diagnosed unresectable pleural mesothelioma. Now in
@TheLancet
@CDNCancerTrials
@curemeso
#CCTG
IND227 trial results published in
@TheLancet
concludes that the addition of pembrolizumab to platinum–pemetrexed improved overall survival in patients with
#pleural
#mesothelioma
0
14
27
2
24
73
Straight shooter award and promoted to Associate Professor of Medicine
@HopkinsMedicine
in the same week! Not bad going
@ClareRock1
We are very proud of you!
12
3
71
Neoadjuvant and adjuvant pembrolizumab immunotherapy now approved by US FDA for pts with lung cancer that can be removed by surgery!
#lcsm
0
22
72
Showtime after a great day at
@NYLungCancerFdn
! With
@JulieBrahmer
@NaglaAKarimMD
@triparnasen
& Karen Kelly
@IASLC
2
1
72
First adjuvant immunotherapy approved for surgical lung cancer!. Approved for PD-L1 + resected stage II-IIIA after platinum chemo. Benefit clear for PD-L1 50%+ but much less apparent for 1-49%. Nevertheless an important day in the history of lung cancer care!
#LCSM
FDA approved atezolizumab (Tecentriq, Genentech) for adjuvant treatment following resection and platinum-based chemotherapy stage II-IIIA NSCLC with PD-L1 expression on ≥1% of tumor cells. FDA also approved VENTANA PD-L1 (SP263) Assay as a CDx.
#lcsm
2
31
65
4
21
72
Docetaxel still stands, the anti-trop2 ADC sacituzumab does not improve OS after prior platinum doublet and immunotherapy for lung cancer. Is docetaxel the most (unfairly) maligned drug in oncology?
#lcsm
5
19
69
The new
@US_FDA
label with new lung cancer indication for neoadj chemo-nivolumab. EFS hazard ratio of 0.63 favoring neoadj chemo-nivo. Overall survival not yet mature but is HR 0.57 at first interim analysis 👀 . Just 3 doses of neoadjuvant chemo-immunotherapy = a big difference!
FDA approved nivolumab (Opdivo, BMS) with platinum-doublet chemotherapy for resectable non-small cell lung cancer in the neoadjuvant setting. This represents the first FDA approval for neoadjuvant therapy for early-stage NSCLC.
#OCENewsBurst
4
41
98
5
11
69
Just saw one of our pts w
#mesothelioma
who enrolled in our
@PrECOGonc
study of chemo-Durva in 2018, still with tumor response ~6 years out, off treatment for almost 5 yrs!
@curemeso
@ValsamoA
@RamalingamMD
2
13
69
Out now in
@CCR_AACR
from Drs.
@josephcmurray
Lavanya Sivapalan &
@ValsamoA
! Tracking response to immunotherapy is increasingly a reality -
0
18
68
Liquid Biopsy Predicts Immunotherapy Response and Toxicity in Patients with Advanced Lung Cancer | Johns Hopkins Medicine
2
24
67
Great to catch up with the dynamic duo of lung cancer patient advocacy! The amazing
@TerriConneran
@KRASKickers
&
@jillfeldman4
@LUNGevity
!
@ASCO
wouldn’t be ASCO with them! I also now have my comfy new
@KRASKickers
socks!
#LCSM
2
5
67
We will present one of the two primary endpoints of the CheckMate 816 neoadjuvant chemo-IO trial for stage IB-IIIA NSCLC, pathological complete response (pCR), at the
#AACR21
plenary this Saturday! A huge effort by surgeons, oncologists and patients across the world.
#LCSM
#tssm
I’m optimistic that we are on the cusp of a new era of care for operable
#lungcancer
patients!
@FordePatrick
@SBroderickMD
#lcsm
#tssmn
#AACR21
0
6
14
6
11
67
Surprising results, PACIFIC-2 trial - durvalumab during & after concurrent chemoradiation - negative in stage 3 lung cancer. Makes one wonder if COAST outcomes closer to reality for CRT>Durva & highlights the work we still need to do in this disease.
#lcsm
5
25
65
Elegant work from Drs. Puig-Saus, Ribas and colleagues showing that a small number of strongly immunogenic mutations in each tumor likely drive response to anti-PD-1 immunotherapy. Outstanding integration of lab and clinic.
0
32
63
Great news for patients who are newly diagnosed with mesothelioma - first new systemic treatment approved in >15yrs!
@curemeso
#mesothelioma
Today the FDA approved the combination of nivolumab plus ipilimumab as first-line treatment for adult patients with unresectable malignant pleural
#mesothelioma
0
31
64
1
19
63
Pt in her early 40s, extensively metastatic lung cancer, “no target” on a few diff attempts at DNA seq (editorializing - please don’t biopsy bone for lung cancer diagnosis!) or liquid biopsy, repeat tissue biopsy & RNA seq = EML4-ALK translocation! Christmas came early!
#lcsm
0
3
61
Excellent work Dr.
@michaelconroy
w
@MolecularOncLab
@ValsamoA
Michael was our Linehan Advanced Oncology Fellow for past 2 yrs & will join faculty
@MSKCancerCenter
🇮🇪 oncologists
@cancertrials_ie
7
5
60
Come work with us
@HopkinsThoracic
@HopkinsMedicine
in 2023! We are recruiting for a new medical oncology faculty member focused on head and neck & thoracic cancers. IMGs are welcome. Please reach out if you are interested!
#lcsm
#lcsm
1
14
60
LEAP-007 trial of pembrolizumab + lenvatinib or placebo negative for OS in PD-L1 1% or greater first line metastatic NSCLC. Looking at you TIGIT? 🤞
#lcsm
4
18
59
Clinical trial eligibility needs to be simplified. Spent 45 mins reading pts chart & the protocol of a phase 3 trial (that I gave advice on during its design phase 🤦♂️) & I still am not 100% sure.
@FDAOncology
@EMA_News
& others could make this happen
0
6
59
More doubts about role (likely minimal) of PD-1 pathway blockade in EGFR mutant advanced lung cancer. KN-789 does not show a significant benefit for chemo-pembro vs chemo alone after prior osimertinib.
#lcsm
2
14
58
Adjuvant atezo after adjuvant chemotherapy in resected stage IB–IIIA lung cancer (IMpower010)
Clear benefit PD-L1 50%+ HR 0.43 for DFS. No clear benefit PD-L1 neg. PD-L1 1-49%? HR 0.87, not significant may need to wait for OS in this group
#lcsm
1
18
58
Anatomy of a phase 1 clinical trial. I was institutional PI for an international phase 1 study looking at a novel IO agent, FPI globally mid 2015, opened at hopkins in late 2015, accrued final pt late 2018, manuscript published 2021. Signed close out docs today, 7.5yrs later!
5
4
58
Excellent presentation by
@DrMarkAwad
of exploratory neoadj nivo-ipi arm vs chemo of
#cm816
. Improved pCR, EFS and trend toward improved OS. Striking early crossing of EFS curves suggests chemo is still needed in this setting.
3
15
55
Neoadjuvant chemo-immunotherapy AND adjuvant IO for lung cancer from Drs.
@HwakeleeMD
@DoctorJSpicer
& colleagues! EFS HR 0.58, pCR rate 18.1%. Great study & confirms benefit of neoadj! Still not clear who needs adjuvant IO?
#lcsm
1
14
55
Great day of discussion & lots of tough decisions w friends
@thenasheffect
@_ShankarSiva
@MMarmarelis
@jdoningtonmd
@LeciaSequist
&
@MARIANOPROVENCI
at the
#asco24
program committee led by the inimitable Alberto Chiappori!
@ASCO
1
5
55
The next generation of KRAS inhibitors? Promising durable response rate in lung cancer and other cancers harboring G12C mutations with divarasib, congrats & thanks to pts and Dr.
@DocSacher
& colleagues.
#lcsm
2
8
54
Former
@HopkinsThoracic
fellow Dr.
@erica_nakajima
(now
@FDAOncology
) will be presenting this abstract in the oral abstract session
@ASCO
- interesting!
1
6
54
Great news for pts whose lung cancer harbors a specific exon 20 mutation in the EGFR gene, amivantamab has been approved by FDA
#LCSM
Today, FDA approved the first targeted therapy for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations.
1
35
79
0
11
53
Almost take off for
#ESMO23
to hear about new breakthroughs & renew collaborations including our neoadjuvant consortium with Drs. Tina Cascone,
@DoctorJSpicer
@MARIANOPROVENCI
, seriously Mariano what’s with the clouds?
2
2
53
FDA officials raise concerns with immunotherapy overuse for early-stage cancer patients:
#AACR24
– Endpoints News
1
20
53
Remarkable results from Prof.
@MARIANOPROVENCI
& team
@gecp_org
- 70% of pts with clinical stage IIIA NSCLC cancer-free at 3 yrs after neoadjuvant nivo-chemo. Strong assoc between ctDNA clearance during neoadj therapy & long term benefit.
0
20
53
Congratulations
@DrJNaidoo
who developed this investigator initiated trial from concept to publication! Anecdotally we have seen pts with leptomeningeal carcinomatosis who benefit from immunotherapy, this is among the first prospective trials to show that IO can help
#LCSM
New
#JITC
article: Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
@DrJNaidoo
@JulieBrahmer
@evanlipson
@FordePatrick
1
21
47
3
7
53
Dr. Cascone’s stylish tie vs. Dr.
@DoctorJSpicer
sockless chic? Whatever about periop vs neoadjuvant we may need
@dieworkwear
to sort this out…
#ESMO23
5
6
53
Congratulations all, we are all really looking forward to working with you! Also it looks like ranks of Irish oncologists
@hopkinskimmel
are rebuilding after departure of
@AdrianmurphyMD
@DrJNaidoo
! Dr. Colum Dennehy will be joining from
@RCPI_news
@UCCMedHealth
Welcome!
Congrats and welcome to our newest
@HemOncFellows
. We're so excited you all will be joining us July 1, can't wait to see you and meet you all in person.
#1Family1Fellowship
8
17
113
2
8
51
With the recent press releases on immunotherapy for surgical lung cancer, watch for CheckMate 816 (neoadj chemo-nivo for 3 doses only) update at
#ELCC23
March 30. Dr.
@nicogirardcurie
will report overall survival at 3 yrs. Two yr follow up looked good, will benefit hold up?
#lcsm
Perioperative immunotherapy for resectable NSCLC will be a very crowded space. Press release tells us AEGEAN and KEYNOTE 671 hit their endpoints. Expect a lot of cross-trial comparisons over the next year or two. Ready for the next wave of trials to further refine delivery!
#LCSM
1
56
121
2
23
51
Chemo-PD1 improves survival vs. chemo for newly diagnosed mesothelioma! Which is better chemo-IO or ipi nivo? Enroll in
#DREAM3R
! Open across USA/AUS/NZ, phase 3 of chemo-durvalumab vs. ipi nivo.
@curemeso
@perth_meso_dr
@PrECOGonc
3
13
51
The addition of nivo to chemo increased pCR from 2.2% w chemo alone to 24% w chemo-nivo (p<0.0001). pCR was assessed by central pathologists who were blinded to trial arms. Surgical specimens had a median of 10% residual tumor cells after chemo-nivo vs 74% after chemo alone.
3
20
51
Beautiful day sailing on the Chesapeake, US naval academy sailors in the distance. For any budding onc fellows considering their ERAS choices - lots of (social distancing friendly) activities near
@hopkinskimmel
!
2
3
50
Looking forward to a great group joining
@HopkinsMedicine
in July. Including Dr.
@drRachelJKeogh
from Ireland 🇮🇪
@RCPI_news
@cancertrials_ie
@AlCRIproject
We are thrilled to introduce our incoming
@Hopkins_HemOnc
fellowship class - what a brilliant & inspiring group of physicians. Can't wait to have you all here in Baltimore!
@hopkinskimmel
@kamarroneMD
@redcell_doc
@JZimmermanMDPhD
@LeukDocWebster
@MarkYarchoan
#AnaDeJesusAcosta
4
16
112
2
9
51